Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.32 |
| ▸ | TTR | P02766 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | GABRP | O00591 | 1/20 | 0.31 |
| ▸ | GABRD | O14764 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3582253 | 1.00 | KDM4E (0.36) | KDM4EALDH1A1GAAHPGDHIF1A | |
| SCHEMBL3581580 | 0.86 | KMT2A (0.32) | KDM4EALDH1A1GAAHPGDHIF1A | |
| SCHEMBL3581574 | 0.86 | KMT2A (0.32) | KDM4EALDH1A1GAAHPGDHIF1A | |
| SCHEMBL3576193 | 0.79 | MAPT (0.40) | KDM4EALDH1A1HPGDKMT2ALMNA | |
| SCHEMBL3576187 | 0.79 | MAPT (0.40) | KDM4EALDH1A1HPGDKMT2ALMNA | |
| SCHEMBL3568981 | 0.78 | KMT2A (0.39) | KDM4EALDH1A1GAAHPGDHIF1A | |
| SCHEMBL3585644 | 0.75 | TSHR (0.36) | KDM4EALDH1A1GAAHPGDHIF1A | |
| SCHEMBL544004 | 0.73 | KMT2A (0.41) | KDM4EALDH1A1GAAHPGDHIF1A | |
| SCHEMBL31487609 | 0.70 | CNKSR1 (0.42) | ALDH1A1TTRRAB9AMAOBMAPT | |
| SCHEMBL3576279 | 0.68 | PLA2G2A (0.36) | KDM4EALDH1A1HPGDKMT2AGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2098513-B1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-01-21 | — | — | EP | disclosed |
| EP-2098513-B1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-01-21 | — | — | EP | disclosed |
| US-8247429-B2 | Tricyclic compound and pharmaceutical use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-21 | — | — | US | disclosed |
| US-8247429-B2 | Tricyclic compound and pharmaceutical use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-21 | — | — | US | disclosed |
| US-8247429-B2 | Tricyclic compound and pharmaceutical use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-21 | — | — | US | disclosed |
| US-20100010038-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | 00 | 2010-01-14 | — | — | US | disclosed |
| US-20100010038-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | 00 | 2010-01-14 | — | — | US | disclosed |
| US-20100010038-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | 00 | 2010-01-14 | — | — | US | disclosed |
| EP-2098513-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-09-09 | — | — | EP | disclosed |
| EP-2098513-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010038-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | MTNR1A, MTNR1B, XDH | KDM4E 1876/4885ALDH1A1 1673/4885GAA 3103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.